Effects of octreotide on postprandial systemic and hepatic hemodynamics in patients with postnecrotic cirrhosis.
The effects of octreotide on postprandial hemodynamic responses were evaluated in 20 patients with postnecrotic cirrhosis. They were randomly assigned to receive either a 100-micrograms bolus with a 100-micrograms/h infusion of octreotide or a placebo. Placebo administration did not affect any of the hemodynamic values. However, after a liquid meal of 500 kcal, postprandial increases in the hepatic venous pressure gradient and hepatic blood flow were observed in patients receiving placebo, while the systemic hemodynamic values remained unchanged. In contrast, in patients receiving octreotide, the hepatic blood flow was significantly decreased 30 min after administration, while the hepatic venous pressure gradient and the systemic hemodynamic values were not affected. After ingestion of a meal, the mean values of the hepatic blood flows were not significantly different from basal values. Moreover, the wedged hepatic venous pressure, the hepatic venous pressure gradient and the systemic hemodynamic values were not affected by meal ingestion. However, during octreotide infusion, hepatic blood flow 30 min after the meal had a tendency to increase compared to before the meal. In conclusion, octreotide inhibited the postprandial increase in portal pressure in patients with postnecrotic cirrhosis. In addition, octreotide decreased hepatic blood flow in the fasting state. When given before a meal, the increase in blood flow induced by the meal restored the hepatic blood flow to basal levels.
Department of Medicine, Taipei Veterans General Hospital, Taiwan, Republic of China.
H C
HC
Lin
Y T
YT
Tsai
C C
CC
Huang
H C
HC
Meng
F Y
FY
Lee
S S
SS
Wang
S D
SD
Lee
K J
KJ
Lo
D000328:Adult; D000368:Aged; D001794:Blood Pressure / Q000187:drug effects; D004435:Eating / Q000502:physiology*; D005260:Female; D006439:Hemodynamics / Q000187:drug effects* / Q000502:physiology; D006503:Hepatic Veins / Q000187:drug effects / Q000502:physiology; D006509:Hepatitis B / Q000150:complications; D006526:Hepatitis C / Q000150:complications; D006801:Humans; D007262:Infusions, Intravenous; D008099:Liver / Q000098:blood supply* / Q000187:drug effects / Q000503:physiopathology; D008103:Liver Cirrhosis / Q000209:etiology / Q000473:pathology / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000008:administration & dosage / Q000494:pharmacology*; D012039:Regional Blood Flow / Q000187:drug effects; D013997:Time Factors; D014655:Vascular Resistance / Q000187:drug effects / Q000502:physiology
D015282:Octreotide